Figure 4.

CBX7-cPRC1 requires JARID2 and low levels of H3K27me3 to bind to Polycomb target genes

(A) Top: schematic of experimental design. Bottom: western blot analyses for the indicated antibodies on total protein extracts.

(B) Average and tornado plots showing ChIP-Rx enrichments of indicated antibodies at maintained Polycomb targets (n = 2,175) in tazemetostat-treated or DMSO control ESCs.

(C) Tornado plots showing ChIP-Rx enrichments of indicated antibodies in tazemetostat-treated or DMSO control ESCs at maintained Polycomb targets (n = 2,175), grouped into quintiles based on CBX7 abundance difference between DMSO and tazemetostat-treated ESCs.

(D) Genome browser tracks of representative genes from quintile 1 (Nat8I) and quintile 5 (Spata3), showing ChIP-Rx of indicated antibodies in tazemetostat-treated or DMSO control ESCs.

(E) Average and tornado plots showing ChIP-seq and ChIP-Rx enrichments of indicated antibodies in WT, Ezh1/2-dKO, and Ezh1 KO/EZH2-Y726D at maintained Polycomb targets (n = 2,175) grouped into quintiles, as described in (C).

(F) Genome browser tracks of indicated antibodies in Ezh1/2-dKO and Ezh1 KO/EZH2-Y726D at representative genes from Q1 (Nat8I) and Q5 (Spata3).

See also Figure S4.